Antisense Companies in BioPortfolio's Corporate Database
Antisense company data on BioPortfolio. Our corporate data records list over 50,000 company records. Here you can see the latest Antisense companies that have been added to our BioPortfolio's life-science corporate directory.
Search For More Antisense Companies
If you don't find the company you're looking for in the list below, you may wish to search our extensive database for further matches: Search for More Antisense Companies.
More Information about Antisense on BioPortfolio
We have published hundreds of Antisense news stories on BioPortfolio along with dozens of Antisense Clinical Trials. In addition to the corporate data, news and clinical trials, BioPortfolio also has a large collection of PubMed Articles about Antisense for you to read.
Showing "antisense rnai sirna" Companies 1 to 25 of 81
Bio-Path is developing a patented, liposomal drug delivery system and products developed at The University of Texas M. D. Anderson Cancer Center, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development.
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a wide array of important di...
Circadian Technologies Limited
Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), we seek to develop truly novel therapies to extend and improve the lives of cancer sufferers. Circadians strengths are the following: Intellectual Property Circadian owns the worlds largest and mos...
RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene tha...
Altogen Labs (www.altogenlabs.com) is a life sciences company dedicated to providing pre-clinical research services to pharmaceutical and biotechnology organizations worldwide. Specialized contract research organization services include RNAi services, cell banking (MCB and WCB), generation of stable cell lines, assay development, cloning, siRNA encapsulati...
Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology’s potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently...
Permeon Biologics is pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Leveraging its novel Intraphilin™ Technology Platform, which has been exclusively licensed from Harvard University, the company’s next-generation approach is being developed to unlock the full therapeutic...
BerGenBio AS is an oncology-based biopharmaceutical company located in Bergen, Norway, focused on pursuing therapeutic treatments for cancer and supporting the screening and identification of a wide array of potential targets in collaboration with other pharmaceutical companies. BerGenBio has a proprietary platform technology called CellSelect™, which...
Gene Signal (www.genesignal.com) is developing a robust pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions based on its innovative angiogenesis modulating technology. The company’s most advanced therapeutic product is aganirsen (GS-101), an antisense oligonucleotide that has nearly completed...
Arrowhead Research Corporation Axolabs GmbH
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead’s world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range...
BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles withÂÂ...
Dicerna Pharmaceuticals is a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in multiple disease areas based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules. Dicer Substrate Technology is a second generation RNAi ap...
Traversa Therapeutics, Inc. (www.traversathera.com) is a San Diego, California-based biopharmaceutical company engaged in the discovery, development and commercialization of RNAi technologies. The company strives to rapidly advance siRNA platform delivery technologies for use in its internal oncology programs and by sanofi-aventis in targeting a wide varie...
Mirrx Therapeutics is developing a novel microRNA-blocking technology, Blockmirs, which are antisense oligonucleotides that bind to a microRNA binding site on an mRNA. This unique approach blocks single microRNA:mRNA interactions, resulting in extremely targeted regulation of specific mRNAs, thereby potentially reducing unintended effects on gene activity....
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therapeutics’ lead product is AIR645, the first in a new class of inhaled drugs that incorporate proprietary, second-generation antisense chemistry. www.altairthera.com
AVI BioPharma is an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon three platform technologies: - therapeutic cancer vaccines, - gene-targeted drugs (antisense), and, - drug delivery technologies.The Company focuses its three platform technologies on two important clinical areas, cancer and cardiovascular disease. The Company...
We have assembled a world class team to lead us to success. We have brought together highly experienced individuals with strong expertise in their respective areas. Our team possesses the combined expertise of having performed research, development, and regulatory processing for over 25 drugs, of which 10 are approved and the rest are at various advanced clinical stages, at the team members' previ...
MoleculA was founded in 1993 to provide high quality antisense oligonucleotides to researchers worldwide. As the company has grown it has diversified and expanded into other market sectors to meet the critical needs of basic researchers and specialized biopharmaceutical manufacturers. Starting with the introduction of a line of neuropeptides under the brand name of Princeton Peptides in 1994, Mol...
Novosom AG has solved the major obstacle towards DNA therapeutics: Delivery of the therapeutic principle towards the cell interior. Novosom and its partners develop unique DNA based therapeutics in inflammation, oncology and liver diseases. In addition, the company is developing its own pipeline in autoimmune diseases. In 2007, the company plans to file two INDs with partners (oncology and liver d...
Nucleis, Architect in Transgenesis
Nucleis, Architect in Transgenesis, is one of the leading biotech company focusing on custom made transgenic mice models. Thanks to its transgenic expertise, Nucleis offers a wide range of innovative approaches that helps researchers to better address gene discovery issues such as gene regulation and function, and optimise drug developments : gene over-expression, humanized mice, Knock-down (RNAi)...
OligoEngine was developed to improve the way researchers design, purchase, and work with custom oligos. Through this singular resource, users have access to the most complete selection and the most specialized resources: for RNAi, DNA methylation, antisense, genome arrays and more.Researchers use the FREE OligoEngine Workstation to design sequences and purchase oligos, while our procurement system...
Open Biosystems was founded in 2001 by a team of researchers who believe deeply in the power of science to improve our lives, and yours, too. This conviction, coupled with our strong desire to help our customers succeed, motivates our employees and gives us our unrelenting focus on developing and delivering the best life sciences tools, support and services to our customers available in the indust...
Polyplus-transfection SA is focused on developing reagents for intracellular delivery of biomolecules. Its expertise includes in vitro and in vivo delivery of genes, oligonucleotides, siRNA and proteins.Polyplus is an established, reliable partner to reseachers in academic, biotech and pharmaceutical laboratories. The company markets a complete line of reagents through an international network of...
Protein Lounge is a leader in the field of system biology. We have developed many interactive web-based databases and software to help the life-scientists understand the complexity of systems biology. Systems biology efforts focus on understanding cellular networks, protein interactions involved in cell signaling, mechanisms of cell survival and apoptosis leading to development or identification o...
Protiva is a development stage biotechnology company, focused on pharmaceutical products to fight serious human disease. Protiva's proprietary SNALP technology enables the development of novel nucleic acid-based drugs, such as those that utilize siRNA. Protiva was founded in September of 2000 based on technology developed at The University of British Columbia.Protiva's headquarters is in Seattle,...
